<DOC>
	<DOCNO>NCT00002923</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial evaluate effectiveness KRN5500 treat patient metastatic solid tumor .</brief_summary>
	<brief_title>KRN5500 Treating Patients With Metastatic Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose toxicity KRN5500 patient solid malignant tumor . II . Characterize clinical pharmacokinetics KRN5500 patient population . III . Initiate preliminary evaluation antitumor activity KRN5500 patient . IV . Determine recommend Phase II dose KRN5500 . OUTLINE : This dose escalation study . Patients receive KRN5500 IV 1 hour day 1-3 . Courses repeat every 21 day . Patients stable disease partial complete remission continue treatment 6 month beyond complete remission . Cohorts 3 6 patient receive escalate dos KRN5500 . The maximum tolerate dose define dose precede least 2 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : Approximately 30 patient accrue study 9-12 month .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove solid malignant tumor convince clinical , radiographic isotopic evidence dissemination Biopsy proof require doubtful case Must eligible know regimen treatment higher potential efficacy PATIENT CHARACTERISTICS : Age : 15 Performance status : ECOG 02 Life Expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL SGOT SGPT great 2 time normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No history acute myocardial infarction within past 6 month No clinically significant cardiac arrhythmia No New York Heart Association class III IV disease Other : HIV negative No GI bleed bleed tendency Not pregnant nursing Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Must recover prior biologic therapy Chemotherapy : At least 4 week since prior chemotherapy recover At least 6 week since prior nitrosourea mitomycin Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>